2024-10-21
Participating in CPHI Worldwid
Release Time: 2024-11-05
News Source: PharmaCompass
Author: SENOVA—Lucas
Novo's Ozempic, Wegovy linked to lower Alzheimer's risk.
Research published in the journal Alzheimer's & Dementia found that individuals with type 2 diabetes who were treated with semaglutide (Ozempic and Wegovy) had a significantly lower risk of developing Alzheimer's compared to those using other diabetes medications. Semaglutide's neuroprotective effects are believed to stem from its ability to reduce inflammation and oxidative stress, which are common factors in both diabetes and Alzheimer's.
Novo's oral diabetes drug Rybelsus slashes heart-related risks by 14%.
Novo Nordisk said its oral diabetes drug Rybelsus (semaglutide) demonstrated significant cardiovascular benefits in a late-stage trial, reducing the risk of major cardiac events by 14 percent compared to placebo. The positive results mirror the cardiovascular benefits already established by Ozempic, the injectable version of semaglutide, which received FDA approval for reducing cardiovascular risks in type 2 diabetes patients with heart disease in 2020.
